TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE FINNISH GENERAL POPULATION

被引:56
|
作者
Hamalainen, Juha [1 ,2 ]
Isometsa, Erkki [1 ,3 ]
Sihvo, Sinikka [4 ]
Kiviruusu, Olli [1 ]
Pirkola, Sami [3 ]
Lonnqvist, Jouko [1 ]
机构
[1] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, SF-00300 Helsinki, Finland
[2] Eastern Hlth Ctr, Helsinki City Hlth Dept, Dept Psychiat, Helsinki, Finland
[3] Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland
[4] Natl Res & Dev Ctr Welf & Hlth, STAKES, Helsinki, Finland
关键词
treatment; major depressive disorder; general population; MENTAL-DISORDERS; BENZODIAZEPINE USE; UNITED-STATES; PRIMARY-CARE; PSYCHOTROPIC MEDICATION; OUTPATIENT TREATMENT; TREATMENT ADEQUACY; ANXIETY DISORDERS; HEALTH-SERVICES; NATIONAL TRENDS;
D O I
10.1002/da.20524
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Few general population studies of the treatment of major depressive disorder (MDD) have included the whole spectrum of treatments. We estimated the rates of different treatments and the effect of individual and disorder characteristics plus provider type on treatment received. Methods: In the Health 2000 Study, a representative sample (n = 6,005) from the adult Finnish population (>= 30 years) were interviewed (CIDI) in 2000-2001 for the presence of DSM-IV mental disorders during the past 12 months. Logistic regression models were used to examine factors influencing the type of treatment. either pharmacotherapies (antidepressants, anxiolytics, sedatives/hypnotics, antipsychotics) or psychological treatment. Results: Of the individuals with MDD (n = 288), currently 24% used antidepressants, 11% anxiolytics, 16% sedatives/hypnotics, 5% antipsychotics, and 17% reported having received psychological treatment. Overall, 31% received antidepressants or psychological treatment or both; 18% received minimally adequate treatment. Of those 33% (n = 94) using health care services for mental reasons, 76% received antidepressants or psychological treatment or both; 54% received minimal adequate treatment. In logistic regression models, the use of antidepressants was associated with female sex, being single, severe MDD, perceived disability, and comorbid dysthymic disorder; psychological treatment with being divorced, perceived disability, and comorbid anxiety disorder Conclusions: Due to the low use of health services for mental reasons, only one-third of subjects with MDD use antidepressants, and less than one-fifth receives psychological treatment. The treatments provided are determined mostly by clinical factors such as severity and comorbidity, in part by sex and marital status, but not education or income. Depression and Anxiety 26.1049-1059, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:1049 / 1059
页数:11
相关论文
共 50 条
  • [41] The efficacy of vortioxetine for the treatment of major depressive disorder
    Dhir, Ashish
    Sarvaiya, Jayrajsinh
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (12) : 1349 - 1363
  • [42] KETAMINE AS A TREATMENT FOR ADOLESCENT MAJOR DEPRESSIVE DISORDER
    Dwyer, Jennifer B.
    Bloch, Michael H.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S176 - S176
  • [43] Consensus guidelines in the treatment of major depressive disorder
    Rush, AJ
    Crismon, ML
    Toprac, MG
    Trivedi, MH
    Rago, WV
    Shon, S
    Altshuler, KZ
    JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 : 73 - 84
  • [44] Escitalopram for the treatment of major depressive disorder in youth
    Ahn, Joon-Ho
    Patkar, Ashwin A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (14) : 2235 - 2244
  • [45] Interest of scopolamine as a treatment of major depressive disorder
    Rigal, A.
    Mouchabac, S.
    Peretti, C. S.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2016, 42 (06): : 568 - 573
  • [46] Ketamine as a Treatment for Adolescent Major Depressive Disorder
    Dwyer, Jennifer
    Sanacora, Gerard
    Bloch, Michael
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S405 - S405
  • [47] Escitalopram and citalopram in the treatment of major depressive disorder
    Andersen, HF
    Lam, RW
    NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 404 - 405
  • [48] The treatment of cognitive deficits in major depressive disorder
    Baldwin, David S.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2013, 17 : 4 - 4
  • [49] Levomilnacipran for the treatment of major depressive disorder: a review
    Asnis, Gregory M.
    Henderson, Margaret A.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 125 - 135
  • [50] Duloxetine (Cymbalta) for treatment of major depressive disorder
    Cobb, C
    Crichlow, R
    AMERICAN FAMILY PHYSICIAN, 2005, 72 (06) : 1099 - 1101